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Abstract 
The antihypertensive flavonol Quercetin (Q1) is endowed with a cardioprotective effect against 
myocardial ischemic damage. Q1 inhibits angiotensin converting enzyme activity, improves 
vascular relaxation, and decreases oxidative stress and gene expression. However, the clinical 
application of this flavonol is limited by its poor bioavailability and low stability in aqueous 
medium. 
In the aim to overcome these drawbacks and preserve the cardioprotective effects of Quercetin, the 
present study reports on the preparation of five different Q1 analogues, in which all OH groups 
were replaced by hydrophobic functional moieties. 
Q1 derivatives have been synthesized by optimizing previously reported procedures and analyzed 
by spectroscopic analysis. The cardiovascular properties of the obtained compounds were also 
investigated in order to evaluate whether chemical modification affects their biological efficacy. 
The interaction with β-adrenergic receptors was evaluated by Molecular Docking and the 
cardiovascular efficacy was investigated on the ex vivo Langendorff perfused rat heart. 
Furthermore, the bioavailability and the antihypertensive properties of the most active derivative 
were evaluated by in vitro studies and in vivo administration (1 month) on spontaneously 
hypertensive rats (SHR), respectively. 
Among all studied Q1 derivatives, only the ethyl derivative reduced left ventricular pressure (at 10-8 
M÷10-6 M doses) and improved relaxation and coronary dilation. NOSs inhibition by L-NAME 
abolished inotropism, lusitropism and coronary effects. Chronic administration of high doses of this 
compound on SHR reduced systolic and diastolic pressure. Differently, the acetyl derivative 
induced negative inotropism and lusitropism (at 10-10 M and 10-8÷10-6 M doses), without affecting 
coronary pressure. Accordingly, docking studies suggested that these compounds bind both β1/β2-
adrenergic receptors. 
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Taking into consideration all the obtained results, the replacement of OH with ethyl groups seems to 
improve Q1 bioavailability and stability; therefore, the ethyl derivative could represent a good 
candidate for clinical use in hypertension. 
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1. Introduction 
Quercetin (Q1) is the major representative of flavonols, a subclass of flavonoids (Fig. 1). This 
compound is often present in glycosylated form, the associated sugar moiety is usually glucose and, 
although glycosylation can occur at any of the five hydroxyl groups, the most common Quercetin 
glycoside presents the sugar moiety appended at position 3 (isoquercetin). 
The major sources of Q1 are fruits such as apples, citrus, berries and cherries, vegetables such as 
onions and broccoli, and beverages such as red wine and tea (Kaur and Kapoor, 2001). It has been 
also found in several medical plants, such as Ginkgo Biloba, Aesculus Hippocastanum and 
Hypericum Perforatum (Sharma and Gupta, 2010). The interest towards this flavonol is due to its 
wide range of bioactivity. Q1 shows not only antioxidant properties like all the flavonoids (Hayek 
et al., 1997) but also anti-inflammatory (Ferry et al., 1996), antiviral, antibacterial, anticarcinogenic 
(Deschner et al., 1991; Pereira et al., 1996; Verma et al., 1988), liver-protecting, cardiovascular 
(Angelone et al., 2011; Vizcaino et al., 2002) and anti-platelet effects (Pignatelli et al., 2000). 
The mechanisms by which Quercetin exerts these effects are not completely understood, but it is 
plausible that different biochemical processes are involved. For example, the antioxidant properties 
seem to be due to the ability of Q1 to act as a scavenger of free radicals and bind transition metals. 
This capability makes Q1 able to inhibit lipid peroxidation and protect cell membranes and nucleic 
acids from the free radical-mediated molecular damages. 
Several recent studies focused on the Q1 cardiovascular protective effects. In particular, the 
antihypertensive effect of such a flavonol has been extensively studied. This compound resulted 
able to decrease oxidative stress, inhibit angiotensin converting enzyme activity, improve 
endothelium vascular relaxation, and modulate cell signaling and gene expression (Angelone et al., 
2011; Larson et al., 2010; Pignatelli et al., 2000). 
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However, the clinical application of Q1 is limited by its poor bioavailability and low stability in 
aqueous medium, due in particular to the two phenolic hydroxyl groups at position 3 and 7. 
During the last years, several studies have been carried out to enhance the pharmacokinetic 
properties and chemical stability of Q1 and numerous derivatives, showing different biological 
properties, have been identified (Kim et al., 2010). 
Based on the results obtained in our previous study, which demonstrated that Quercetin is able to 
induce biphasic inotropic and lusitropic effects, herein we describe the preparation of five different 
Q1 derivatives in which OH groups have been replaced with hydrophobic functional groups in the 
aim to enhance the lipophilic character of this compound and, thus, improve its bioavailability. 
All the synthesized molecules have been subjected to in vitro tests to estimate their bioavailability 
and in vivo assays to evaluate the cardiovascular effects. 
 
2. Materials and methods 
2.1. Chemistry 
 2.1.1. General Chemical Information 
Melting points were determined using a Veego make silicon oil bath-type melting point apparatus 
and are uncorrected. Purity of the compounds and completion of reactions were monitored by thin 
layer chromatography (TLC) on silica gel plates (60 F254; Merck), visualizing with ultraviolet light 
or iodine vapors. The IR spectra were recorded using KBr disc method on a Shimadzu FT-IR, 
Model 8300. The 1H-NMR spectra (on a Bruker 300/400 MHz spectrometer) were recorded in 
DMSO. Chemical shifts were reported as part per million (δ ppm) using tetramethylsilane (TMS) as 
an internal standard. The assignment of exchangeable protons was confirmed by the D2O exchange 
studies wherever required. Mass spectral data was obtained on a QTRAP Applied Biosystem 
SCIEX spectrometer or on JEOL-SX-102 instrument (JEOL, Tokyo, Japan) by fast atom 
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bombardment (FAB positive mode). Spectral data (IR and NMR) confirmed the structures of the 
synthesized compounds and the purity was ascertained by microanalysis.  
 
2.1.2. 2-(3,4-diacetoxyphenyl)-4-oxo-4H-chromene-3,5,7-triyl triacetate (Q2) 
This compound was synthesized following experimental conditions previously described (Picq et 
al., 1982). 
The crude resulting was purified by column chromatography (chloroform/ethyl acetate, 9:1 as 
solvent). The product was isolated as a white solid, 35% yield. Mp 190°C (chloroform/ethyl 
acetate). 1H-NMR (CDCl3) δ: 7.54-7.50 (m, 2H), 7.31-7.02 (m, 2H), 6.56 (d, 1H, J = 2.1 Hz), 2.42-
2.15 (m, 15H).13C-NMR (CDCl3) δ:169.25, 167.81, 167.74, 156.85, 154.25, 150.41, 144.37, 142.19, 
127.77, 126.42, 123.92, 123.84, 113.88, 108.96, 21.17, 21.02, 20.65, 20.50. IR max:1775, 1645, 
1178, 1149, 1127, 1107, 1074, 1021, 899 cm-1. 
 
2.1.3. 2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-3,5,7-trihydroxy-4H-chromen-4-one (Q3) 
This compound was prepared according to an experimental procedure previously described (Lu et 
al., 2014).  
The crude resulting oil was purified by column chromatography (petroleum ether/ethyl acetate, 4:1 
as solvent). The product was isolated as a yellow solid, 7 % yield. Mp 217°C (petroleum ether/ethyl 
acetate). 1H-NMR (d6-Acetone) δ: 12.0 (s br, 3H, OH); 7.76 (m, 2H); 7.50 (m, 3H); 7.38-7.23 (m, 
6H); 7.09-6.98 (m, 1H); 6.42 (d, 1H); 6.15 (d, 1H). 13C-NMR (CDCl3) δ: 175.13, 162.26, 161.13, 
156.2, 148.89, 147.60, 139.76, 135.68, 129.33, 128.48, 127.51, 126.25, 125.40, 124.53, 122.95, 
108.67, 107.90, 103.82, 98.84, 94.11. IR max: 2800, 1598, 1493, 1260, 1241, 1213, 1187, 1043, 
1018, 697 cm-1. 
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 2.1.4. 2-(2,2-diphenylbenzo[d][1,3]dioxol-5-yl)-4-oxo-4H-chromene-3,5,7-triyl triacetate 
(Q4) 
This compound was synthesized following experimental conditions previously described (Kim et 
al., 2010). 
The product was isolated as a white solid, 32 % yield. Mp 193°C (chloroform/ethyl acetate). 1H-
NMR (d6-Acetone) δ: 7.53-7.31 (m, 5H, Ar); 7.39-7.29 (m, 5H, Ar); 7.07 (m, 3H); 6.88 (m, 2H); 
2.22 (m, 9H). 13C-NMR (CDCl3) δ: 170.09, 169.30, 167.84, 156.81, 155.24, 154.05, 150.33, 149.80, 
147.68, 139.53, 129.42, 128.43, 128.41, 128.40, 128.38, 128.36, 128.35, 128.33, 128.26, 126.26, 
126.25, 126.23, 126.21, 126.18, 123.53, 123.04, 114.69, 113.65, 108.87, 108.74, 108.28, 21.18, 
21.05, 20.66. IR max:1777, 1626, 1496, 1259, 1176, 1138, 1043, 1019, 754 cm-1. 
 
 2.1.5. 2-(3,4-diethoxyphenyl)-3,5,7-triethoxy-4H-chromen-4-one (Q5) 
This compound was prepared according to an experimental procedure previously described (Picq et 
al., 1982).  
The product was isolated as a yellow solid, 20% yield. Mp 123°C (n-hexane – chloroform/ethyl 
acetate). 1H-NMR (CDCl3) δ: 7.78-7.58 (m, 2H, Ar); 7.03-6.83 (m,2H, Ar); 6.34 (m, 1H); 4.28-3.86 
(m, 10H); 1.92-1.09 (m, 12H), 0.89-0.75 (m, 3H). 13C-NMR (CDCl3) δ: 178.90, 164.74, 161.97, 
156.73, 151.07, 148.09, 137.85, 122.98, 122.10, 113.57, 112.17, 111.05, 98.09, 92.56, 68.56, 68.03, 
64.42, 64.17, 29.68, 15.70, 15.62, 14.80, 14.69, 14.56. IR max: 1599, 1474, 1393, 1267, 1214, 
1172, 749 cm-1. 
 
 2.1.6. 3,5,7-tris(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-4H-chromen-4-one (Q6) 
This compound was prepared according to an experimental procedure previously described 
(Bouktaib et al., 2002). 
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The product was isolated as a yellow solid, 15% yield. Mp 121°C (dichloromethane).1H-NMR 
(CDCl3) δ: 7.68- 7.50 (m, 4H), 7.40-7.08 (m, 23 H); 6.9-6.79 (m, 1H); 6.45-6.28 (m, 2H); 5.19-4.89 
(m, 10H). 13C-NMR (CDCl3) δ: 178.82, 164.44, 162.02, 156.66, 156.30, 147.81, 145.56, 137.60, 
137.44, 136.88, 136.63, 136.42, 135.78, 135.64, 128.84, 128.78, 128.73, 128.67, 128.60, 128.49, 
128.33, 128.27, 128.18, 128.01, 127.86, 127.45, 127.33, 127.16, 123.95, 123.43, 122.59, 121.88, 
115.26, 114.86, 113.62, 111.53, 106.20, 98.64, 92.98, 74.34, 74.22, 71.11, 70.84, 70.41. IR 
max:1586, 1255, 1194, 1166, 1123, 1001, 815 cm-1. 
 
2.2.Molecular modelling and docking simulations 
The molecular modelling simulations were performed on an Apple Mac pro 2.66 GHz Quad‐Core 
Intel Xeon, Running Ubuntu 12.04. Different crystal structures of human β2-adrenergic receptors 
were examined in order to identify the putative binding site. The β2-adrenergic receptor bound to 
the partial agonist carazol (PDB ID: 2RH1) was chosen for our docking studies (Cherezov et al., 
2007). 
No human crystal structure of the β1-adrenergic receptor is available, so the meleagris gallopavo β1 
receptor co-crystallised with the partial agonist cyanopindolol has been used (PDB ID: 4BVN) 
(Miller-Gallacher et al., 2014). Due to the high identity with the human β1-adrenergic receptor 
(75% identity) and the conserved amino acids residues of the binding site, no homology model 
preparation was required and the crystal structure was used for the docking studies. 
Docking studies were performed using Glide docking as part of Maestro package (Glide, Maestro 
version 9.5.014, Schrödinger, Inc., New York, NY).The two co-crystallised molecules were selected 
as center of the binding site and, then, the selection was extended to the near amino acids building a 
12 Å grid. A ligands database in Maestro format, prepared using the LigPrep function, was used as 
input for the docking calculation. Ligand docking was performed using Glide SP (standard 
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precision) setting the default values, and no water molecules were considered. The output solutions 
were visual inspected in MOE to identify the interaction between ligand and protein (Molecular 
Operating Environment,http://www.chemcomp.com/MOE-Molecular_Operating_Environment.htm, 
accessed Aug 20,2014). 
 
2.3.Bioavailability studies 
2.3.1. General bioavailability methods 
Hydrochloric acid, pepsin from porcine gastric mucosa, esterase from porcine liver, α-amylase from 
porcine pancreas, pancreatin from porcine pancreas, sodium cholate, sodium dihydrogen phosphate, 
disodium hydrogen phosphate and sodium hydrogen carbonate were purchased by Sigma-Aldrich 
(Sigma Chemical Co., St Louis, MO, USA). All solvents were reagent-grade or HPLC-grade and 
provided by Carlo Erba Reagents (Milano, Italia). Dialysis tubes were provided by Spectrum 
Laboratories Inc., MWCO: 12-14,000 Dalton, U.S.A. Absorption spectra were recorded with a 
Jasco V-530 UV/Vis spectrometer. 
 
2.3.2. In vitro bioavailability studies 
In vitro bioavailability studies were carried out in simulated gastric and intestinal fluids through a 
slight modified dialysis tubing procedure (Chimento et al., 2013). The dialysis tubing method is 
based on two enzymatic phases: pepsin digestion, which occurs in the first two hours, and 
pancreatin digestion, in the following four hours. The two phases are described below. 
Pepsin Digestion. 300μL of a Q5 solution (1.0 mM in DMSO) were mixed with 1.0 mL of a 0.85 N 
HCl solution containing 24000 U of porcine pepsin per mL and 3.0 mL of a sodium cholate solution 
(2% w/v in distilled water). The obtained mixture was introduced into a dialysis bag, which was 
sealed on each end with clamps and immersed in a flask containing 10 mL of a 0.85 N HCl solution 
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(pH 1.0). The flask was then incubated for 2 h into a shaking water bath at 37 ± 0.5°C, simulating 
the human physiological conditions of temperature. 
Pancreatin Digestion. At the end of the 2 h pepsin digestion, the dialysis bag was recovered and 
carefully opened. 11 mg of amylase, 11 mg of esterase and 1.3 mL of a 0.8 M NaHCO3 solution 
containing 22.60 mg porcine pancreatin/mL were added to the peptic digesta. After the digesta and 
enzymes solution were mixed, the dialysis bag was sealed again and placed into a flask with 10 mL 
of a phosphate buffer solution at pH 7.0. The flask was incubated into the shaking water bath at 37 
± 0.5°C for further 4 h. 
In order to evaluate the in vitro bioavailability of the sample, 3 mL of the medium were withdrawn 
from the flask at the time points of two and six hours, after pepsin and pancreatin digestions, 
respectively. The concentrations of the samples were determined by UV/Vis spectroscopy and 
calculated by using the equations obtained from the calibration curves of Q5 standard solutions at 
pH 1.0 and 7.0, respectively. For this purpose, all the prepared standard solutions were analysed by 
UV-Vis spectrophotometer and the correlation coefficient (R2) and slope of the regression equations 
obtained by the method of least square were calculated at pH 1.0 and 7.0, respectively. 
The same procedure was applied to evaluate the bioavailability of Q1, used as control for data 
confrontation. 
Each experiment was repeated three times. 
 
2.4.In vivo studies 
2.4.1. Animals 
Animal care, sacrifice and experiments were in accordance with the Italian law (D.L. 26/2014), the 
Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health 
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(2011), and the Directive 2010/63/EU of the European Parliament on the protection of animals used 
for scientific research.  
 
2.4.2. Perfusion technique 
The performance of the rat heart was evaluated according to the Langendorff technique. Rats were 
anesthetized with ethyl carbamate (2 g/kg rat, i.p.). Hearts were rapidly excised and transferred in 
ice-cold buffered Krebs-Henseleit solution (KHs). Aorta was immediately cannulated with a glass 
cannula and connected with the Langendorff apparatus to start perfusion at a constant flow-rate of 
12 ml/min. in order to avoid fluid accumulation, the apex of the left ventricle (LV) was pierced. A 
water-filled latex balloon, connected to a BLPR gauge (WRI, Inc. USA), was inserted through the 
mitral valve into the LV to allow isovolumic contractions and to continuously record mechanical 
parameters. The balloon was progressively filled with water up to 80 μl to obtain an initial left 
ventricular end diastolic pressure of 5–8 mmHg. Coronary pressure was recorded using another 
pressure transducer located just above the aorta. 
Left ventricular pressure (LVP) was measured by means of a latex water-filled balloon inserted into 
the left ventricle via the left atrium [adjusted to obtain left ventricular end-diastolic pressure 
(LVEDP) of 5–7 mmHg] and connected to a pressure transducer (BLPR gauge;WRI, USA). The 
maximal values of the first derivative of LVP, [+(LVdP/dt)max, mmHg/s], which indicates the 
maximal rate of left ventricular contraction, the maximal rate of left ventricular pressure decline of 
LVP [(LVdP/dt)min, mmHg/s)], the rate pressure product (RPP: HR  LVP, in 
104mmHg·beats/min), used as an index of cardiac work, and LVEDP were used to assess cardiac 
function. Mean coronary pressure (CP, mmHg) was calculated as the average of values obtained 
during several cardiac cycles. 
12 
 
The perfusion solution consisted of a modiﬁed non recirculating KHs containing 113 mM NaCl, 4.7 
mM KCl, 25 mM NaHCO3, 1.2 mM MgSO4, 1.8 mM CaCl2, 1.2 mM KH2PO4, 11 mM glucose, 1.1 
mM mannitol, 5 mM Na-pyruvate. pH was adjusted to 7.4 with NaOH (1 M) and the solution was 
equilibrated at 37 °C by 95% O2– 5% CO2. All drug-containing solutions were freshly prepared 
before the experiments.  
 
Statistics. Statistical analysis was performed by one-way ANOVA and Newman-Keuls Multiple 
Comparison Test, when appropriate. Differences were considered statistically significant at p<0.05. 
GraphPad Prism software, version 5 (GraphPad Software, San Diego, CA) will be used for all the 
statistical analysis.  
 
2.4.3. Drugs-stimulated preparations 
For each drug, preliminary experiments (data not shown) obtained by the repetitive exposure of 
each heart to one concentration of the single drug (10-8 M) revealed the absence of desensitization. 
Thus, concentration-response curves were generated by perfusing each cardiac preparation with 
KHs enriched with increasing concentrations of either Q2, or Q3, or Q4, or Q5, or Q6, or Q1 (from 
10-10 M to 10-6 M) for 10 min. 
 
3. Results and discussion 
3.1. Chemical 
 The preparation of five Q1 derivatives, in which all the OH groups have been substituted 
with different hydrophobic functional groups, has been performed optimizing previously reported 
procedures as depicted in the Scheme 1 (Bouktaib et al., 2001; Kim et al., 2010; Lu et al., 2014; 
Picq et al., 1982). 
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3.2. Molecular docking studies 
A series of molecular docking studies were performed to investigate the putative binding mode of 
the reported compounds on both β1 and β2 receptors. Quercetin (Q1) seems able to bind both 
receptors (Fig.2). In the β2-receptor Q1 forms two H-bonds with Asp113, while in the β1 it 
establishes three different H-bonds (Asn129, Tyr207, Asn319). The possibility to bind both 
receptors could lead to β1/ β2-adrenergic biological effects caused by Quercetin. 
Interestingly, compounds Q4 and Q6 could not be docked in any of the receptors, probably because 
of their rigidity and steric hindrance. This observation could possibly explain the total absence of 
activity for Q6 and the very small activity for Q4. Compound Q2 gave good docking results only 
for the β2-receptor (Fig.3 (A)) interacting with Tyr199 and occupying the active site as Q1. Once 
again, we could not generate any useful docking result from the β1-receptor. Q3 and Q5 docks well 
with both receptors. Q3 forms H-bonds with Aps121 and Ser211 in the β1 and with Asp113 and 
Ser203 in the β2 (Fig.3 (B,C)). Q5 does not seem to establish any specific hydrogen bond but it 
occupies extensively the active site (Fig.3 (D,E)). 
From these studies, we can say that Q1 and the other most active compounds Q2, Q3 and Q5, could 
potentially interact with the β-adrenergic receptors. Due to the similar active site geometry (Fig.3 
(F)) between the two types of β-receptors, it is likely that the reported compounds can easily bind 
both targets balancing the different biological effects linked with the specific β-adrenergic 
receptors. 
 
3.3. Ex vivo studies 
3.3.1. Basal conditions 
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After 20 minutes of stabilization, the following basal recordings were measured: LVP = 85±1.7 
mmHg, heart rate (HR) = 276±7.3 beats/min, RPP = 3.3±0.12 104 mmHg beats/min, CP = 66±1.7 
mmHg, +(LVdP/dT) max = 2768±82.1 (mmHg/sec) and-(LVdP/dT) max = 1547±28.7 (mmHg/sec). 
Endurance and stability of the preparation, analyzed by measuring performance variables every 10 
min, showed that the heart preparation is stable for up to 180 min on the perfusion apparatus. 
 
3.3.2.Dose-response curves of Q1-Q6 
The biological efficacy of Q1 and its modified derivatives was evaluated by analyzing the 
hemodynamic performance of the rat heart ex vivo perfused according to Langendorff. We found 
that application of Q1 from 10-10 M to 10-6 M resulted in positive inotropic and lusitropic effects at 
low concentrations (10-10 to 10-8 M) and in negative inotropic and lusitropic effects at higher 
concentrations (10-7 and 10-6 M). Q1 induced vasodilation at low concentration (10-10 to 10-8 M) 
while it did not modify HR (data not shown). These effects are similar to those previously published 
by Angelone et al.(2011). Q2 determined a significant negative inotropic effect revealed by the 
reduction of LVP, LVdP/dt max and RPP, and a negative lusitropic effect revealed by the reduction 
of LVdP/dt min. Q2 did not significantly affect HR, while it induced vasoconstriction at all 
concentrations tested (Fig.4). Contrarily, Q3 was unable to affect the rat cardiac performance, 
except for a small vasoconstriction detected at high concentration (10-7 M) (Fig. 5). Q4 exposure 
induced a decrease in LVP and LVdP/dt max at 10-6 M, while it unchanged the other cardiac 
parameters (Fig.6). Notably, Q5 induced a dose-dependent significant negative inotropic effect 
revealed by the reduction of LVP, LVdP/dt max and RPP, and a negative lusitropic effect revealed 
by the reduction of LVdP/dt min (Fig. 4). Q5 did not change HR, but it determined a significant 
reduction of the coronary pressure at high concentrations (from 10-8 M to 10-6 M) (Fig. 7). Q6 did 
not affect the cardiac performance (Fig. 8). 
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3.4. Cellular mechanism of action of Q5 
In the present study, we analysed the transduction pathway activated by Q5 since, contrary to all 
others quercetin derivatives here tested, it induces a coronary vasodilation which is significant at 
high doses. This coronary effect is similar to that elicited by quercetin on the ex vivo rat heart, 
already shown by Angelone et al. (2011), and resembles the coronary activity of flavonols (Duarte 
1993 and 2001). It has been reported in the mammalian heart, that β1- and β2-adrenoceptors 
represent the main intermediaries of the cardiac response to adrenergic stimulation, each of them 
modulates different signal pathways resulting in different outcomes on cardiac function. β1-
adrenoceptor, the most abundant subtype in mammalian heart (Brodde et al., 2006), induces the 
activation of the stimulatory G protein (Gαs)/adenylyl cyclase (AC)/cAMP/cAMP-dependent 
protein kinase A (PKA) pathway (Woo and Xiao, 2002), while β2-adrenoceptor has been shown to 
regulate an alternative signaling through the activation of inhibitory G proteins (Gαi) (Woo and 
Xiao, 2002). The main signal pathway regulated by β2-adrenoceptors through Gαi is the 
phosphatidylinositol-3 kinase (PI3K) signaling cascade and the activation of the Nitric Oxide 
pathway (Conti et al., 2013).Our docking studies indicated that Q5 binds both β1- and β2-
adrenergic receptors. However, since Q5 determined negative inotropism, lusitropism and 
vasodilation, we suggest that it mainly interacts with β2 adrenergic receptor. In order to explore the 
intracellular β2-dependent mechanism of action by which Q5 determines negative inotropism and 
lusitropism and vasodilation, hearts were treated with the NOSs inhibitor L-NAME in the presence 
of Q5 (Fig. 9). Results indicated that L-NAME abolished Q5-dependent cardiac effects suggesting 
the obligatory role of NO in mediating the intracellular signaling activated by this derivative. 
 
3.5. In vitro bioavailability studies 
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Most of the natural compounds suffer of low in vivo bioavailability. Possible reasons for a reduced 
bioavailability are low intrinsic activity, low degree of absorption, high metabolization rate, poor 
activity of metabolites and/or rapid elimination (Bhattaram et al., 2002). Despite its strong activity, 
several studies in the past decades related the low bioavailability of Q1 to poor absorption and rapid 
metabolism (Cai et al., 2013). 
In the attempt to improve Q1 bioavailability, several molecular modifications could be introduced. 
Considering the hydrophilic/hydrophobic ratio of the molecule, most of the hydrophilic character of 
Q1 is provided by –OH groups. In order to improve its hydrophobicity, as well as its capability to 
cross biological membranes, the modification of these groups in more hydrophobic ones is an 
interesting strategy. Indeed, the ethylation of hydroxyl groups (Q5) resulted in a more hydrophobic 
molecule than Q1 (see Table 1 with clogP). Interestingly, the other substitutions that increased 
significantly the hydrophobicity of the analogues (Q3, Q4 and Q6), not only might lead to very 
poorly soluble compounds (cLogP >5), but they could also be rapidly hydrolysed in vivo.  
Table 1.  
Quercetin derivative Weight  logP (o/w) slogP 
Q1 (Quercetin) 302.238 2.032 2.0109 
Q2 512.423 2.9887 2.8948 
Q3 466.445 6.5850 5.5837 
Q4 592.566 7.3080 6.0282 
Q5 442.508 4.8087 5.2618 
Q6 752.863 12.0437 12.4953 
 
For this reason, Q5 derivative was selected for the evaluation of the in vitro bioavailability, 
according to the dialysis tubing procedure, a fast, reliable and low cost method, which allows to 
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evaluate the bioavailability of different kinds of compounds. The test was conducted on Q1 as well, 
used as control to compare bioavailability data. 
Bioavailability is defined as the percentage of the tested molecule recovered in the bioaccessible 
fraction, after in vitro digestion, in relation to the original non-digested sample and it can be 
calculated by the following Equation (1): 
 ��݋ܽ�ܽ��ܾܽ���ݐ� ሺ%ሻ = ��݋ܽܿܿ�ݏݏ�ܾ�� ܿ݋݊ݐ�݊ݐ�݋ݐܽ� ܿ݋݊ݐ�݊ݐ × ͳͲͲ     ሺͳሻ 
 
The in vitro evaluation of the bioavailability of Q5 has shown an enhanced bioaccessibility since 
the first two hours (the obtained results were reported in Table 2), reaching almost 19% at the end 
of the experiment. On the other hand, according to our procedure, the bioavailability of unmodified 
quercetin (Q1) showed a total percentage slightly under 11%. This result suggests that improving 
lipophilicity by ethylation is important in increasing the amount of Q1 that could potentially reach 
the bloodstream. 
 
 
Table 2. 
In vitro bioavailability (%) of Q5 and Q1 after pepsin (2 h) and pancreatin (4 h) digestions. 
Time point Q5 bioavailability (%) Q1 bioavailability (%) 
Pepsin digestion (2 h) 8.5 ± 0.7 4.4 ± 0.9 
Pancreatin digestion (4 h) 10.3 ± 0.8 6.3 ± 0.8 
Total in vitro bioavailability (6 h) 18.8 ± 1.2 10.7 ± 1.3 
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Previous studies reported data about in vivo bioavailability of Q1. Reinboth et al. (2010) reported a 
4% absolute bioavailability of Q1 in dogs, while the bioavailability of unchanged Q1 in pigs is 
0.54% (Ader et al., 2000). Also oral bioavailability evaluation in human volunteers has been 
conducted in the past, showing that less than 2% of orally administered Q1 can be found in 
bloodstream (Gugler et al., 1975). Compared to these results, Q5 displays a greatly improved 
bioavailability.  
 
3.6. In vivo studies 
Due to coronary dilation, the negative inotropism and lusitropism induced by Q5, this quercetin 
derivative (10nM) was administrated to the rat for 1 month in the drinking water in order to analyse 
its anti-hypertensive properties. For this purpose, the Spontaneous Hypertensive Rat (SHR) were 
used as models of human hypertensive condition, and Wistar Kyoto rats as normotensive control 
(n=6 for each groups) (Harlan, Italy). Tail cuff method was used for weekly measures of systolic 
and diastolic blood pressure (BP). Tail cuff was connected to a pneumatic pulse transducer and a 
programmed electro-sphygmomanometer (BP-2000 series II; blood pressure analysis system, 
Visitech System). Blood pressures measured are reported in Table 3. 
 
Table 3 
Systolic and diastolic BP values measured in WKY and SHR before and after Q5 administration. 
Significance of difference was evaluated by t-test;*=p<0.05. 
 
 
Systolic BP (mmHg) Diastolic BP (mmHg) 
 
Before Q5 After Q5 Before Q5 After Q5 
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WKY 120 ± 2.3 119 ± 2.5 83 ± 3.9 75 ± 3.3 
SHR 197 ± 6.6 145 ± 7.0* 132 ± 6.3 101 ± 5.9* 
 
These data suggest that the chronic administration of the Q5 determines a reduction of systolic and 
diastolic pressure in the presence of hypertension. 
 
4. Conclusion 
Poor bioavailability and low stability of Quercetin could be determining factors of its beneficial 
effects; therefore, in the present research study, a small series (Q2-Q6) of variously substituted Q1 
derivatives was synthesized in the aim to overcome these limitations without affecting the 
cardioprotective properties of this polyphenol.  
The best structural combination required for cardiovascular activity seems to be functional 
substitution of each OH group with an ethyl moiety (Q5 derivative). Accordingly, among all the 
tested compounds, only this derivative determined a significant reduction of the left ventricular 
pressure (LVP), from10-8 M to 10-6 M. This compound also increased relaxation and coronary 
dilation, and inotropism, lusitropism and coronary effects were abolished by NOSs inhibition by L-
NAME. Furthermore, the chronic administration of higher doses of such a compound on SHR rats 
determined a significant reduction of systolic and diastolic pressure.  
The acetyl derivative Q2 instead, induced a negative inotropism and lusitropism significant at 10-10 
M and from 10-8 to 10-6 M, while it did not modify the coronary pressure.  
The obtained results suggest that the substitution of all OH groups present in Q1 molecule with 
ethyl groups improves the bioavailability and stability of this flavonol. Moreover, the synthesized 
ethyl derivative Q5 has been shown good antihypertensive properties; therefore, it could represent a 
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good candidate for clinical use in the presence of hypertension and, thus, warrant further preclinical 
and mechanistic investigation. 
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Figure Captions 
Fig. 1. Chemical Structure of Quercetin. 
Fig. 2.Q1 docked in the β1 (purple) and β2-adrenergic (blue) receptors. 
Fig. 3. Q2 docked in the β2-adrenergic receptor (A). Q3 docked in the β1- (B) and β2-adrenergic 
(C) receptors. Q5 docked in the β1- (D) and β2-adrenergic (E) receptors. Superposition of the β2 
(blue) and β1 (purple) active sites (F). 
Fig. 4. Dose-dependent response curves of Q2 (10-10 M – 10-6 M) on LVP, HR, (LVdP/dT)max, 
(LVdP/dT)min, RPP and CP, on Langendorff perfused rat heart preparations. Percentage changes 
were evaluated as means ± SEM of 7 experiments. Significance of difference from control values 
was evaluated by one-way ANOVA; P= 0<0.05. 
Fig. 5. Dose-dependent response curves of Q3 (10-10 M – 10-6 M) on LVP, HR, (LVdP/dT)max, 
(LVdP/dT)min, RPP and CP, on Langendorff perfused rat heart preparations. Percentage changes 
were evaluated as means ± SEM of 7 experiments. Significance of difference from control values 
was evaluated by one-way ANOVA; P= 0<0.05. 
Fig. 6. Dose-dependent response curves of Q4 (10-10 M – 10-6 M) on LVP, HR, LVdP/dT max, 
LVdP/dT min, RPP and CP, on Langendorff perfused rat heart preparations. Percentage changes 
were evaluated as means ± SEM of 7 experiments. Significance of difference from control values 
was evaluated by one-way ANOVA; P= 0<0.05.  
Fig. 7. Dose-dependent response curves of Q5 (10-10 M – 10-6 M) on LVP, HR, LVdP/dT max, 
LVdP/dT min, RPP and CP, on Langendorff perfused rat heart preparations. Percentage changes 
were evaluated as means ± SEM of 7 experiments. Significance of difference from control values 
was evaluated by one-way ANOVA; P= 0<0.05.  
Fig. 8. Dose-dependent response curves of Q6 (10-10 M – 10-6 M) on LVP, HR, LVdP/dT max, 
LVdP/dT min, RPP and CP, on Langendorff perfused rat heart preparations. Percentage changes 
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were evaluated as means ± SEM of 7 experiments. Significance of difference from control values 
was evaluated by one-way ANOVA; P= 0<0.05. 
Fig. 9. Effects of Q5 (100 nM) before and after treatment with the NOSs inhibitor L-NAME (10 
µM) on LVP, LVdP/dT max, LVdP/dT min, and CP, on Langendorff perfused rat heart 
preparations. Percentage changes were evaluated as means ± SEM of 5 experiments. Significance of 
difference from control values was evaluated by t-test; P= 0<0.05. 
 
 
 
Scheme Captions 
Scheme 1. Reagents and reaction conditions for Q1 derivatives synthesis. 
